Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Farmers Insurance
Fish and Richardson
Queensland Health
Deloitte

Generated: July 19, 2019

DrugPatentWatch Database Preview

Patent: 9,969,683

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,969,683
Title:Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. The breast cancer includes metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, AR-positive refractory breast cancer, AR-positive metastatic breast cancer, AR-positive and ER-positive breast cancer, triple negative breast cancer, advanced breast cancer, breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments, and metastasis in a subject suffering from breast cancer. The method comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
Inventor(s): Dalton; James T. (Lakeland, TN), Steiner; Mitchell S. (Germantown, TN), Narayanan; Ramesh (Cordova, TN), Ahn; Sunjoo (Daejeon, KR)
Assignee: GTX, INC. (Memphis, TN)
Application Number:13/953,492
Patent Claims:see list of patent claims

Details for Patent 9,969,683

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech KADCYLA ado-trastuzumab emtansine VIAL; SINGLE-USE 125427 002 2013-02-22 ➤ Sign Up GTX, INC. (Memphis, TN) ➤ Sign Up RX search
Genentech KADCYLA ado-trastuzumab emtansine VIAL; SINGLE-USE 125427 001 2013-02-22 ➤ Sign Up GTX, INC. (Memphis, TN) ➤ Sign Up RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08 ➤ Sign Up GTX, INC. (Memphis, TN) ➤ Sign Up RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up GTX, INC. (Memphis, TN) ➤ Sign Up RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up GTX, INC. (Memphis, TN) ➤ Sign Up RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up GTX, INC. (Memphis, TN) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 9,969,683

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2014011220 Jan 16, 2014
World Intellectual Property Organization (WIPO) 2014011220 Mar 05, 2015
United States of America 10258596 Apr 16, 2019
United States of America 2014018433 Jan 16, 2014
United States of America 2014080905 Mar 20, 2014
United States of America 2014350102 Nov 27, 2014
United States of America 2016128968 May 12, 2016
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Covington
Teva
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.